ArticleFrontiers in bioinformatics2025
Bacteriocin prediction through cross-validation-based and hypergraph-based feature evaluation approaches.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriocins offer a promising solution to antibiotic resistance, possessing the ability to target a wide range of bacteria with precision. Thus, there is an urgent need for a computational model to predict new bacteriocins and aid in drug development. This work centers on constructing web-based predictive models using the XGBoost machine learning algorithm, based on the physicochemical properties, structural characteristics, and sequence profiles of protein sequences. We employed correlation analyses, cross-validation, and hypergraph-based techniques to select features. Cross-validated feature selection (CVFS) partitions the dataset, selects features within each partition, and identifies common features, ensuring representativeness. On the contrary, hypergraph-based feature evaluation (HFE) focuses on minimizing hypergraph cut conductance, leveraging higher-order data relationships to precisely utilize information regarding feature and sample correlations. The XGBoost models were built using the selected features obtained from these two feature evaluation methods. We also analyzed the feature contributions directly from the best model using SHapley Additive exPlanations (SHAP). Our HFE-based approach achieved 99.11% accuracy and an AUC of 0.9974 on the test data, overall outperforming the CVFS-based feature evaluation method and yielding results comparable to existing approaches. The most influential features are related to solvent accessibility for buried residues, followed by the composition of cysteine. Our web application, accessible at https://shiny.tricities.wsu.edu/bacteriocin-prediction/, offers prediction results, probability scores, and SHAP plots using both cross-validation- and hypergraph-based methods, along with previously implemented approaches for feature selection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.